Eli Lilly and Company is still poised to benefit from huge market growth ahead in weight-loss drug sales. For investors looking to invest here, the stock provides the opportunity to protect ...

The rest of our medicines performed within our expectations." Looking ahead, Lilly expects the sales momentum of Mounjaro and Zepbound to continue in 2025, alongside contributions from new ...

The rest of our medicines performed within our expectations." Looking ahead, Lilly expects the sales momentum of Mounjaro and Zepbound to continue in 2025, alongside contributions from new medicines ...

Eli Lilly's looking ahead to 2025 with adjustments to their assumptions. BMO Capital sees potential for the company to outperform expectations through continued effective commercial strategies and ...

Earnings Report 5.302 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.954 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.770 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

According to InvestingPro analysis, Eli Lilly currently trades at a P/E ratio of 79.6, reflecting high market expectations for future growth. Eli Lilly's looking ahead to 2025 with adjustments to ...

The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes ... and the economic environment ahead, drove the momentum.